StocksMedium•9 October 2026•
1 min read
Argenx Shares Tumble 12% as Late-Stage Autoimmune Study Halted
Key Facts
1Argenx shares tumbled 12% following the discontinuation of its late-stage Sjogren's disease study.
2The company reported positive FB102 data in celiac disease as a contrasting pipeline development.
Argenx shares tumbled 12% following the discontinuation of its late-stage Sjogren's disease study. Zacks reported that the decision came even as the company announced positive data for its FB102 candidate in treating celiac disease as a contrasting pipeline development.
The significant drop in share price follows the halt of the Phase 3 clinical trial, which often impacts projected revenue growth despite progress in other areas of the company's portfolio. Argenx was experiencing downward momentum in trading on October 9, 2026, as markets reacted to the clinical trial update.